July 1, 2021 07:33 AM EDT

Another repurposed drug bites the dust in Covid-19 as Angion bails on organ damage drug effort

Kyle Blankenship

Since the early days of the pandemic, drugmakers have taken a broad approach to repurposing other drugs in their pipeline against severe Covid-19 — a mission …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Another repurposed drug bites the dust in Covid-19 as Angion bails on organ damage drug effort

Kyle Blankenship

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

New study will try to stop Alzheimer’s decades before it begins, using experimental Eli Lilly drug

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

We’re about to find out which RFK Jr. will show up at HHS

Astellas shakes up management despite impressive nine-month earnings

Illumina added to China's blacklist following Biosecure Act, tariffs

An­oth­er re­pur­posed drug bites the dust in Covid-19 as An­gion bails on or­gan dam­age drug ef­fort

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Another repurposed drug bites the dust in Covid-19 as Angion bails on organ damage drug effort